Sunday, November 8, 2026

USD/EUR Over 1% Down In The Last 21 Sessions

USD/EUR Over 1% Down In The Last 21 Sessions

(VIANEWS) - USD/EUR (USDEUR) has been up by 1.74% for the last 21 sessions. At 15:10 EST on Monday, 27 March, USD/EUR (USDEUR) is $0.93.

USD/EUR's yearly highs and lows, it's 3.556% up from its 52-week low and 11.658% down from its 52-week high.

Volatility

USD/EUR's last week, last month's, and last quarter's current intraday variation average was a negative 0.19%, a negative 0.13%, and a positive 0.47%, respectively.

USD/EUR's highest amplitude of average volatility was 0.53% (last week), 0.55% (last month), and 0.47% (last quarter), respectively.

News about

  • Usd/jpy climbs to fresh daily high, around mid-131.00s amid receding safe-haven demand. According to FXStreet on Monday, 27 March, "A generally positive tone around the equity markets undermines the safe-haven Japanese Yen (JPY), which, in turn, is seen as a key factor acting as a tailwind for the USD/JPY pair. ", "Apart from this, expectations that the Bank of Japan (BoJ) will tweak its bond yield control policy and whittle down its massive stimulus under new Governor Kazuo Ueda might contribute to capping gains for the USD/JPY pair. "
  • Usd/jpy: neutral view amidst global banking turmoil – morgan stanley. According to FXStreet on Monday, 27 March, "Analysts at Morgan Stanley shift their view on the USD/JPY pair to neutral from their previous long recommendation.", "With the risk of the market pricing in further policy convergence, we close our long USD/JPY position and turn neutral until things become much clearer."
  • Usd/jpy price analysis: bulls find support at 130.00 amid banking support measures. According to FXStreet on Monday, 27 March, "The USD/JPY experienced a sharp rebound after finding support at the 130.00 mark. ", "The fundamental picture for the USD/JPY portrays a downside bias, but the Relative Strength Index (RSI) signals a possible pullback due to slightly oversold conditions."

More news about USD/EUR (USDEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com